OmniAb (OABI) Net Cash Flow (2021 - 2026)
OmniAb (OABI) reported Net Cash Flow of $3.5 million for Q1 2026, up 121.08% year-over-year from $1.6 million in Q1 2025, and up 216.89% on a QoQ basis from -$3.0 million in Q4 2025.
OmniAb (OABI) has 6 years of Net Cash Flow data on file, last reported at $3.5 million in Q1 2026.
- Quarterly Net Cash Flow rose 121.08% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.2 million (up 322.26% YoY) and the FY2025 annual result came in at -$2.1 million, down 118.45% from the prior year.
- Net Cash Flow advanced to $3.5 million in Q1 2026 per OABI's latest filing, from -$3.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $33.8 million in Q4 2022 and bottomed at -$16.7 million in Q1 2025.
- The 5-year median for Net Cash Flow is $1.0 million (2024), against an average of $2.1 million.
- The widest annual swing landed in 2022, when Net Cash Flow jumped 9442.55%; it then slumped 932.32% in 2025.
- Tracing OABI's Net Cash Flow over 5 years: stood at $33.8 million in 2022, then plunged by 114.44% to -$4.9 million in 2023, then surged by 107.41% to $362000.0 in 2024, then tumbled by 932.32% to -$3.0 million in 2025, then soared by 216.89% to $3.5 million in 2026.
- Per Business Quant, the three latest OABI Net Cash Flow figures stand at $3.5 million (Q1 2026), -$3.0 million (Q4 2025), and $10.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn | 3.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.52 Mn |
| Mar 31, 2026 | 3.52 Mn |
| Dec 31, 2025 | -3.01 Mn |
| Dec 31, 2025 | -3.01 Mn |
| Sep 30, 2025 | 10.26 Mn |
| Sep 30, 2025 | 10.26 Mn |
| Jun 30, 2025 | 7.39 Mn |
| Jun 30, 2025 | 7.39 Mn |
| Mar 31, 2025 | -16.71 Mn |
| Mar 31, 2025 | -16.71 Mn |
| Dec 31, 2024 | 362,000.00 |
| Dec 31, 2024 | 362,000.00 |
| Sep 30, 2024 | 6.44 Mn |
| Sep 30, 2024 | 6.44 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 2.70 Mn |
| Mar 31, 2024 | 2.70 Mn |
| Dec 31, 2023 | -4.89 Mn |
| Dec 31, 2023 | -4.89 Mn |
| Sep 30, 2023 | 259,000.00 |
| Sep 30, 2023 | 259,000.00 |
| Jun 30, 2023 | -1.76 Mn |
| Jun 30, 2023 | -1.76 Mn |
| Mar 31, 2023 | -10.53 Mn |
| Mar 31, 2023 | -10.53 Mn |
| Dec 31, 2022 | 33.84 Mn |
| Dec 31, 2022 | 33.84 Mn |
| Dec 31, 2021 | -362,203.00 |
| Dec 31, 2021 | -362,203.00 |
| Sep 30, 2021 | 236.08 Mn |
| Sep 30, 2021 | 236.08 Mn |